Wed, May 11, 2022

Joel Beatty Upgraded (ARWR) to Buy and Decreased Target to $60 on, May 11th, 2022

Joel Beatty of Baird, Upgraded "Arrowhead Pharmaceuticals, Inc." (ARWR) to Buy and Decreased Target from $71 to $60 on, May 11th, 2022.

Joel has made no other calls on ARWR in the last 4 months.



There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Joel's Rating of Hold.



This is the rating of the analyst that currently disagrees with Joel


  • Madhu Kumar of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Wednesday, January 19th, 2022